Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

Lancet. 2001 Jan 20;357(9251):195-6. doi: 10.1016/S0140-6736(00)03594-7.


The UK was the first country to use meningococcal serogroup C conjugate (MCC) vaccines, which were licensed on the basis of immunogenicity and safety data but without a formal efficacy study. Increased surveillance during the first 9 months since introduction has shown that short-term efficacy of the MCC vaccine in England was 97% (95% CI 77-99) for teenagers and 92% (65-98) for toddlers. These early results confirm the superiority of MCC over plain C polysaccharide vaccines, which are ineffective in young children.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • England
  • Humans
  • Immunization Programs
  • Infant
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines*
  • Treatment Outcome
  • Vaccines, Conjugate*


  • Meningococcal Vaccines
  • Vaccines, Conjugate